Federal Register Notice: FDA has determined the regulatory review period is 3,602 days for Dainippon Sumitomo Pharma Co.’s Latuda (lurasidone hydrochloride)for extending a patent which claims the human drug product. Latuda is indicated as an atypical antipsychotic agent for the treatment of patients with schizophrenia. To view this notice, click here.
